Navigation Links
Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Orexigen((R) )Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at two upcoming investor conferences. The details are as follows:

    Morgan Stanley Global Healthcare Unplugged Conference
    Date:  September 15, 2009
    Time:  9:45am Eastern Time
    Location:  Grand Hyatt Hotel, New York
    Speaker:  Michael Narachi, President and Chief Executive Officer

    NewsMakers in the Biotech Industry Conference
    Date:  September 16, 2009
    Time:  11:30am Eastern Time
    Location:  Millennium Broadway Hotel, New York
    Speaker:  Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead investigational product, Contrave((R),) has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second product, Empatic(TM), is in the later stages of Phase 2 clinical development, with results expected in the second half of 2009. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found athttp://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Appoints Mark Booth Chief Commercial Officer
2. Orexigen(R) Therapeutics to Speak at Canaccord Adams Global Growth Conference
3. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
4. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
5. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
6. Orexigen(R) Therapeutics to Present at Upcoming Meetings
7. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
8. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
9. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... the international market with three research projects accepted for presentation at the 33rd ... . Nearly 10,000 participants – including some of the world’s top thought leaders ...
(Date:6/27/2017)... ... June 27, 2017 , ... The recent vote by the ... a disease gives new hope to patients and hopefully sheds new light on the ... M.D. , an infertility expert and founding partner of Texas Fertility Center . ...
(Date:6/27/2017)... Iowa (PRWEB) , ... June 27, 2017 , ... ... technology license agreement whereby DuPont gains exclusive rights to the ERS patent portfolio ... ERS was formed to commercialize the foundational intellectual property (IP) of the CRISPR-Cas ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water ... Board of Directors. Dr. Henig will bring a wealth of scientific experience in the ... the Chief Technical and Scientific Officer of four major global companies in the last ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):